Adverse events were frequent, and most were gastrointestinal-related, including nausea, vomiting, diarrhea, constipation.

With 13 states offering coverage, it’s already a $3.9 billion cost. Some state officials say reducing obesity will save programs money in the long run.

We found that, of the 12 GLP-1 (drugs) identified by our search, the greatest mean body weight reduction was reported in randomized controlled trials of retatrutide, tirzepatid

McGill University researchers say their study has found GLP-1 drugs are safe and effective for treating obesity and overweight adults without diabetes. The authors say the findings support using the medication to treat those who are overweight and obese among otherwise healthy patients.